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ABSTRACT  
Objective: To develop and validate simple, rapid and sensitive spectrophotometric method for the assay of four antimuscarinic antagonists, namely 
oxybutynin (OXB), solifenacin (SOL), tolterodine (TOL) and fesoterodine (FES) in bulk and pharmaceutical formulations.  
Methods: The proposed method is based on the reaction of the selected drugs with eriochrome cyanine R (ECR) in buffered aqueous solution at pH 
1.0. The formed ion-pair complexes were extracted with dichloromethane and measured quantitatively with maximum absorption at 464 nm. All 
variables that affect on color intensity such as pH, buffer volume and concentration of ECR and extractive solvents were studied and optimized. 
Results: The calibration graphs were linear over the concentration range of 4–24, 4–32, 4–32 and 2–22 µg/ml for OXB, SOL, TOL and FES, 
respectively. The stoichiometry of the reaction was found to be 1:1 in all cases. Molar absorptivity values were found to be 2.043×104, 1.856×104, 
1.798×104 and 2.856×104 l/mol/cm for OXB, SOL, TOL and FES, respectively. Excipients which used as an additive in commercial formulations did 
not interfere in the analysis.  
Conclusion: The developed method was successfully applied to determine OXB, SOL, TOL and FES in pharmaceutical preparations. The developed 
method can be used for quality control and routine analysis where time, cost effectiveness and high specificity of analytical technique are of great 
importance. 
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Oxybutynin, solifenacin, tolterodine and fesoterodine as an 
antimuscarinic/anticholinergic muscle relaxant, used to reduce 
urinary frequency, urinary urgency and urinary incontinence in 
people with an overactive bladder. They works by relaxing the 
involuntary detrusor muscle in the wall of the bladder by blocking 
muscarinic/cholinergic receptors present on the surface of the 
muscle cells and thus prevents acetylcholine from acting on these 
receptors [1–4]. 
Oxybutynin (OXB), (α-cyclohexyl-α-hydroxybenzenacetic acid-4-
(diethylamino)-2-butynyl esters) (fig. 1a) an anticholinergic agents 
is a tertiary amine that mainly acts as a direct smooth muscle 
relaxant and displays weak antimuscarinic activity [5, 6]. A survey of 
the literature revealed that few methods have been reported for the 
determination of OXB such as UV and visible spectrophotometry [7–
9], voltammetric [10], HPLC methods [11–14], gas chromatography 
in serum [15], Polymeric matrix membrane sensors were used for 
stability-indicating potentiometric determination of OXB and 
differential pulse polarography [16].  
Solifenacin (SOL) [17–20], chemically, is butanedioic acid (3R)-1-
azabicyclo [2.2.2] octan-3-yl(1S)-1-phenyl-1,2,3,4-tetrahydro-
isoquinoline-2-carboxylate (fig. 1b), having an empirical formula of 
C27H32N2O6 and molecular weight of 480.5528 g/mol. Literature 
survey reveals chromatographic methods for the analysis of 
solifenacin and have been applied for the quantification of SOL in 
bulk, biological fluids and commercial formulations [21–27]. Though 
the chromatographic methods are precise the instrumentations are 
expensive and required critical experimental conditions. Hence 
these techniques are not applied for routine analysis of SOL. The 
spectrophotometric methods are still popular for the routine 
analysis in quality control laboratories because they are precise, 
simple, fairly accurate and cost-effective. Very few literatures are 
cited on spectrophotometric methods [28, 29].  
Tolterodine (TOL) has chemical name of ®-N, N-diisopropyl-3-(2-
hydroxy-5-methyl phenyl)-3-phenyl-propanamine L-hydrogen 
tartrate (fig. 1c). The methods reported in the literature for its 
determination either in biological matrix or in pharmaceutical 
formulations are spectrophotometric [30–33], LC [34–36], HPLC 
[37–41], potentiometric [42] and electrochemical methods [43, 44]. 
Fesoterodine (FES) [45, 46] chemically, is designated as isobutyric 
acid 2-(®-3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl) 
phenyl ester hydrogen fumarate (fig. 1d). A survey of chemical 
literature as shown that few articles are available for the 
determination of fesoterodine fumarate using LC and LC-MS [47–
49], HPLC [50–52], UV [53–55] and electrophoresis [56]. An attempt 
has been made to develop a simple and rapid visible 




a- OXB [5] 
 
b- SOL [17] 
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c- TOL [38] 
 
d- FES [45] 
Fig. 1: Chemical structure of the studied drugs 
 
MATERIALS AND METHODS 
Apparatus 
All the absorbance spectral measurements were made using 
spectroscan 80 D double-beam UV/Visible spectrophotometer 
(Biotech Engineering Ltd. (UK), with wavelength range 190 nm ~ 1100 
nm, spectral bandwidth 2.0 nm, with 10 mm matched quartz cells. 
Reagents and solutions 
All the chemicals were of analytical or pharmaceutical grade and 
used without further purification. Double distilled de-ionized water 
was used to prepare all solutions. A stock solution of pure selected 
drugs was prepared by dissolving 20 mg of the selected drugs in a 
100 ml calibrated flask. Working solutions of lower concentrations 
were freshly prepared by appropriate dilution with water. A 2×10-
3M of eriochrome cyanine R (ECR) (Sodium 4-[(1-hydroxy-
naphthalen-2-yl-hydrazinylidene]-7-nitro-3-oxo-Y-naphthalene-1-
sulfonate) stock solution were prepared by dissolving 107.28 mg of 
dye (99% purity) in distilled water and diluting to 100 ml in a 
measuring flask with distilled water. Series of buffer solutions of 
KCl-HCl (pH=1.0–2.2), potassium hydrogen phthalate-HCl (pH=2.2–
4.0) and NaOAc-HCl (pH=3.2–6.8) were prepared by standard 
methods.  
All pharmaceutical preparations were obtained from local market. 
Tolterodine tablets (2 mg TOL/tablet) manufactured by Sabaa 
International Company for Pharmaceuticals and Chemical 
Industries, Egypt, Uripan (5 mg OXB/tablet) manufactured by 
ADWIA Co. S.A.E. 10th of Ramadan City, Egypt, Sofenacin (5 mg 
SOL/tablet) manufactured by Marcyrl Pharmaceutical Industries, El 
Obour City, Egypt and fesoterodine fumarate is Toviaz 4 mg/tab 
(Pfizer Company, Egypt). 
General recommended procedures 
Into a series of separating funnels, accurately measured aliquots of 
4–24 µg/ml for OXB, 4–32 µg/ml for SOL, 4–32 µg/ml for TOL and 
2–22 µg/ml for FES were pitted out. Then, 2.5 ml of 2×10-3M of ECR, 
1.0 ml of buffer solution of pH=1.0 were added and the volume was 
completed to 10 ml with distilled water. The ion-pairs were 
extracted with 10 ml of dichloromethane by shaking for 2.0 min and 
then, the combined dichloromethane extracts were dried over 
anhydrous sodium sulphate. The absorbance of colored ion-pair 
complexes was measured within 20 min of extraction at 464 nm 
against a reagent blank prepared in the same manner except for 
addition of drugs. A calibration graph was constructed for each drug 
and the concentration of unknown samples can be deduced by using 
of calibration graph. 
Procedure for tablets 
At least ten tablets of each commercial pharmaceutical formulation 
of the drugs were weight into a small dish, powdered and mixed 
well. An accurate weight of the powder equivalent to 10 mg of each 
drugs was dissolved in distilled water, filtered into a 100 ml 
calibrated flask and diluted to the mark with water. Further dilution 
was made to obtain working range concentration and analyzed as 
the above procedure for the analysis. 
RESULTS AND DISCUSSION 
Absorption spectra 
Ion-pair extraction spectrophotometry has received considerable 
attention for quantitative estimation of many pharmaceutical 
compounds [57–60]. This technique depends on the reaction of a 
drug that has basic cationic nitrogen and an anionic dye, where a 
highly colored ion-pair complex is formed. OXB, SOL, TOL and FES 
reacted with an anionic dye (ECR) in acidic buffer to form ion-pair 
complexes, which are soluble in dichloromethane. These complexes 
have an absorption maximum at 464 nm against a reagent blank and 




Fig. 2: Absorption spectra of 24 μg/ml OXB with ECR dye complex extracted in dichloromethane 
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Optimization of the reaction condition 
The optimization of the methods were carefully studied to achieve 
complete reaction formation, highest sensitivity and maximum 
absorbance. Reaction conditions of the ion-pair complexes were 
found by studying with preliminary experiments such as pH of the 
buffer, type of organic solvent, dye concentration and shaking time 
for the extraction of ion-pair complexes.  
Effect of pH 
It was observed that the effective extraction of the complex depends 
on the type of buffer used and its pH. The effect of pH was studied by 
extracting the colored complexes in the presence of various buffers, 
such as KCl-HCl (pH 1.0–2.2), NaOAc–HCl (pH 1.9–4.92) and NaOAc–
AcOH (pH 3.4–5.6). It was noticed that the maximum color intensity 
and constant absorbances were observed in KCl-HCl of pH=1.0 for all 
the drugs. The volume of buffer solution added was studied and 
adding 1.0 ml buffer solution of pH=1.0 attained complete color 
development. For the highest color intensity and maximum 
absorbance, the buffer solution should be added after mixing the 
drug–dye solution at neutral pH.  
Choice of organic solvent 
Different organic solvents as dichloromethane, carbon tetrachloride, 
chloroform and ether were tested as extractive solvents for the 
proposed method. Dichloromethane was preferred to other solvents 
for its selective and obtained the highest absorbance with 
dichloromethane. It was also observed that only one extraction was 
adequate to achieve a quantitative recovery of the complexes and 
the shortest time to reach the equilibrium between both phases. 
Shaking time of 0.5–5 min provided constant absorbance and hence, 
1.0 min was selected as the optimum shaking time. 
Effect of dye concentration  
The effect of ECR concentration on the intensity of the color 
developed at the selected wavelength and constant drugs 
concentration was tested using different volumes of ECR (0.5–5 ml). 
It was observed that 2.5 ml of 2×10-3M ECR were necessary for the 
maximum color development of the ion-pair complexes. After this 
volume, the absorbance remains constant by increasing the volume 
of the reagent.  
Sequence of addition and phase ratio 
Although it is not a fundamental factor, the most favorable 
sequence is drug-reagent–buffer–dichloromethane) for the highest 
absorbance and stability. The complexes with these sequences 
remain stable at least for 12 h. The ratio of aqueous to organic 
phase was ineffective and the ratio 1:1 was chosen for extraction 
of the colored species.  
Stability of the ion-pair complexes 
The stability of the ion-pair complexes formed between the studied 
drugs and ECR was evaluated. Although the ion-pairs were obtained 
instantaneously, constant absorbance readings were obtained after 
not less than 5.0 min of standing at room temperature (25±2 °C). 
Ion-pairs were stable for at least 12 h without any change in color 
intensity or in λmax.  
Composition of ion–pair complexes 
In order to establish a molar ratio between OXB and ECR dyestuff 
used, Job's method of continuous variation was applied. In this 
method, solutions of drug and dyestuff with identical molar 
concentrations were mixed in varying volume ratio in such a way 
that the total volume of each mixture was the same. The absorbance 
of each solution was measured and plotted against the mole fraction 
of the drug. This measurement showed that 1:1 complex was formed 
through the electrostatic attraction between positive protonated 
OXB+ and negative ECR-. The possible reaction mechanism is 
proposed and given in fig. 3. 
Validation of proposed method 
The following validation parameters were tested according to the 
guidelines set by the international conference on harmonization 
(ICH) [61]: linearity, accuracy, precision, limit of detection (LOD) 
and the limit of quantitation (LOQ). 
Linearity and range 
The Beer’s law range, molar absorptivity, Sandell’s sensitivity, 
regression equation, slope, intercept and correlation coefficient 
determined for each drug are given in table 1. A linear relationship 
was found between the absorbance and the concentration of each 
drug in the range of 4–24 µg/ml for OXB, 4–32 µg/ml for SOL, 4–32 
µg/ml for TOL and 2–22 µg/ml for FES (fig. 4). Regression analysis 
of Beer’s law plotted at λmax reveals a good correlation (r2 = 0.9976–
0.9989). The graphs showed a negligible intercept, which was 
calculated by the least-squares method’s regression equation, A = 
a+bC (where A is the absorbance of 1.0 cm layer, b is the slope, a is 




Fig. 3: Structure of OXB–ECR ion pair complex 
 
Table 1: Analytical parameters and optical characteristics of the proposed method 
Parameters Drugs 
OXB SOL TOL FES 
Beer's law limit, μg/ml 4–24 4–32 4–32 2–22 
Molar absorptivity, l/mol/cm 2.04×104 1.85×104 1.79×104 2.85×104 
Sandell’s sensitivity, ng/cm2 19.27 25.88 26.44 18.47 
Correlation coefficient ® 0.9976 0.9994 0.9989 0.9983 
Linear regression equation*     
Sy/x 0.0263 0.0125 0.0143 0.0110 
Intercept (a) 0.1499 0.2378 0.2436 0.1556 
Slope (b) 0.0462 0.0315 0.0301 0.0457 
SD of slope (Sb) 1.57×10-3 5.01×10-4 6.05×10-4 1.32×10-3 
SD of intercept (Sa) 0.0540 0.0237 0.0265 0.0227 
LOD, µg/ml 0.0357 0.0523 0.0548 0.0361 
LOQ, µg/ml 0.1082 0.1587 0.1661 0.1094 
OXB: oxybutynin, SOL: solifenacin, TOL: tolterodine, FES: fesoterodine, *A = a+bc, where A is the absorbance and C is the concentration of drug in 
µg/ml. 
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Fig. 4: Calibration curve of ion-pair complexes of OXB, SOL, TOL and FES with ECR against a blank 
 
Detection and quantification limits 
The detection limit (LOD) for the proposed method was calculated 
using the following equation [61].  
LOD = 3.3 s/k 
Where s is the standard deviation of replicate determination values 
under the same conditions as for the sample analysis in the absence 
of the drug and k is the sensitivity, namely the slope of the 
calibration graph. In accordance with the formula, the detection 
limits obtained for the absorbance were found to be 0.0357 µg/ml 
for OXB, 0.0523 µg/ml for SOL, 0.0548 µg/ml for TOL and 0.0361 
µg/ml for FES.  
The limits of quantification, LOQ, defined as:  
LOQ = 10 s/k 
According to this equation, the limits of quantification were found 
to be 0.1082 µg/ml for OXB, 0.1587 µg/ml for SOL, 0.1661 µg/ml 
for TOL and 0.1094 µg/ml for FES. A comparison of the 
performances between the proposed method and those of 
reported methods for the studied drugs is summarized in table 2. 
It can be seen that the detection limit of the present work is lower 
than that found in the reported methods. 
Accuracy and precision 
In order to determine the accuracy and precision of the 
recommended procedure five replicate determinations at three 
different concentrations of the studied drugs were carried out. 
Precision and accuracy were based on the calculated relative 
standard deviation (RSD, %) and relative error (RE, %) of the found 
concentration compared to the theoretical one, respectively (table 3) 
and indicate that the proposed method is highly accurate and 
reproducible. 
Effect of interferences 
In order to evaluate the selectivity of the proposed method for the 
analysis of pharmaceutical formulations, the effects of the presence 
of excipients and additives, which can occur in real samples, were 
investigated. It was found that the presence of the common 
excipients of tablets such as talc, starch, gelatin, glucose, sulfate, 
acetate, phosphate and magnesium stearate did not interfere with 
the determination of the studied drugs at the levels normally found 
in dosage forms. 
 
Table 2: Comparison of linear range and detection limits for the studied drugs with reported methods 
Drug Methods Linear range, µg/ml Detection limit, µg/ml Ref 
OXB Squarewave cathodic adsorptive stripping voltammetry 1-18 0.100 10 
Differential pulse cathodic adsorptive stripping voltammetry 1-17.6 0.2300 10 
Ion-association complex with Tropaeoline OOO 1.0-7.5 0.0621 9 
Ion-association complex with Alizarin Red-S. 2.0-15 0.1112 9 
 Extractive-spectrophotometric with eriochrome cyanine R 4-24 0.0357 Proposed method 
SOL HPLC method 2-100 0.0700 22 
RP-HPLC 20-70 0.100 24 
Extractive-spectrophotometric with eriochrome cyanine R 4-32 0.0523 Proposed method 
TOL Zero order derivative 30-180 0.6600 31 
RP-HPLC 100-300 0.1600 38 
Extractive-spectrophotometric with eriochrome cyanine R 4-32 0.0548 Proposed method 
FES Capillary electrophoresis 2-100 0.5700 56 
Second-order derivative UV spectrophotometric 2-24 0.3800 55 
Extractive-spectrophotometric with eriochrome cyanine R 2-22 0.0227 Proposed method 
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Table 3: Evaluation of intra-day accuracy and precision of the proposed method 
Drugs  Intra-day accuracy and precision 
Taken μg/ml Founda μg/ml Recovery, % RSD, % REb, % 
OXB 4 3.9999 99.998 2.107 -0.002 
12 11.9995 99.996 1.527 -0.004 
20 19.9992 99.996 1.156 -0.004 
SOL 8 7.9995 99.994 1.581 -0.006 
20 19.998 99.994 1.703 -0.006 
28 27.998 99.996 2.095 -0.004 
TOL 8 7.9995 99.994 1.760 -0.006 
20 19.9988 99.994 2.059 -0.006 
32 31.9980 99.994 1.786 -0.006 
FES 4 3.9998 99.996 1.126 -0.004 
10 9.9994 99.994 1.393 -0.006 
16 15.9993 99.996 1.911 -0.004 
OXB: oxybutynin, SOL: solifenacin, TOL: tolterodine, FES: fesoterodine, aMean value of five determinations, bRE: Relative error. 
 
Tablets analysis 
The proposed method was successfully applied to the determination 
of OXB, SOL, TOL and FES in their commercially tablets. Various 
formulations were analyzed to examine the applicability of the 
developed method and the results were tabulated in table 4. The 
results were reproducible with low RSD values. The average percent 
recoveries obtained were quantitative (95.78–100.73), indicating 
the good accuracy of the method.  
The results of analysis of the commercial tablets and the recovery 
study of drugs suggested that there is no interference from any 
excipients (such as starch, talc, gelatin, magnesium stearate, sulfate, 
glucose, acetate and phosphate), which are present in tablets. 
  
Table 4: Assay results of OXB, SOL, TOL and FES in pharmaceutical formulations by the proposed method 
Drug formulations Drug taken μg/ml Drug founda μg/ml Recovery, % RSD, % REb, % 
Uripan tabletsc, 5 mg/tab 4 3.899 97.494 2.965 -2.50 
12 12.051 100.430 1.442 0.43 
20 19.772 98.860 2.542 -1.14 
sofenacin tabletsd, 5 mg/tab 8 7.976 99.706 3.084 -0.294 
20 19.878 99.392 2.329 -0.608 
28 28.206 100.738 2.283 0.738 
Tolterodine tabletse, 2 mg/tab  8 7.754 96.936 3.649 -3.064 
20 19.736 98.680 2.934 -1.32 
32 31.107 97.210 3.655 -2.79 
Toviazf, 4 mg/tab 4 3.908 97.700 2.626 -2.3 
10 9.578 95.784 3.724 -4.216 
16 15.796 98.726 2.039 -1.274 
aMean value of five determinations, bRE: Relative error, cProduced of Adwia pharmaceuticals Company, Egypt, dProduced of Marcyrl Pharmaceutical 
Industries, Egypt, eProduced of Sabaa international company for Pharmaceutical and chemical industry, Egypt, fProduced of Pfizer Company, Egypt. 
 
CONCLUSION 
The proposed method characterized by using simple reagents which can 
be afforded by any ordinary analytical laboratory. The method is 
sufficiently sensitive to permit determination even down to 2.0 µg/ml. 
The developed method is highly reliable owing to the stability of the dye 
and ion-pair complexes, which are finally measured. The proposed 
method is simple, precise, accurate and convenient. Therefore, it can be 
useful for routine analyses and quality control assay of the examined 
drugs in raw material and in tablets without fear of interference caused 
by the excipients expected to be present in tablets. This is for the first 
time that spectrophotometric method is being reported for the assay of 
FES in pure form and also in its pharmaceutical formulation. 
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